Eric Hoefer - Arcus Biosciences Executive

Mr. Eric Hoefer is Chief Commercial Officer of the Company. During the span of Mr. Hoefer 20year career in biopharma, he was instrumental to the development and commercialization of 15 new medicines, including Avastin, Tarceva, Tecentriq, and Imfinzi . His diverse experience spans global product strategy, global marketing, product development, and U.S. marketing and sales leadership. Mr. Hoefer was most recently at AstraZeneca, where he led ImmunoOncology Global Marketing and launched Imfinzi as the first immunooncology medicine approved in the curativeintent lung cancer setting. Prior to joining AstraZeneca, Mr. Hoefer launched seven new medicines during an approximately 14year tenure with RocheGenentech. From 20152017, Mr. Hoefer coled the creation of Roche Phase 1b2 IO platform to adaptively assess and accelerate novel combination approvals across seven tumor types. Also, during his tenure, Mr. Hoefer led the commercial development for latestage GI oncology assets. Mr. Hoefer began his biopharma career in primary care and specialty care sales for GlaxoWellcome. In 2002, as a Congressional Health Policy Analyst for the Chairman of the House Ways Means Committee, he was involved in developing the Medicare Modernization Act, including Part B reform and the Part D prescription drug benefit since 2019.